The primal blueprint: how CamMed mimics evolution to reinvent self-amplifying RNA
CamMed CEO Dr. Ahmet Can Berkyurek on an AI-discovered, single-protein replicase drawn from biology's most ancient machinery — and his case for building it in the UK
Sarah Boyce's Avidity: A deep dive into one of the fastest growing biotechs of all time
Avidity Biosciences has achieved successful data readouts for all three of its programs in Phase 1/2 clinical trials, initiated its first Phase 3 trial, and raised over $1.1 billion this year.